Shanghai RAAS Blood Products Co Ltd Class A Total Assets
Shanghai RAAS Blood Products Co Ltd Class A total assets. Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) holds total assets worth CN¥37.46 Billion CNY (≈ $5.48 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Shanghai RAAS Blood Products Co Ltd Clas market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
Total assets of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025. This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's total assets have evolved over time, based on quarterly financial data. See Shanghai RAAS Blood Products Co Ltd Clas stock price for real-time trading data and today's change.
Shanghai RAAS Blood Products Co Ltd Class A - Asset Composition Analysis
Shanghai RAAS Blood Products Co Ltd Class A Total Assets Breakdown (December 2025)
Shanghai RAAS Blood Products Co Ltd Class A total assets breakdown as of December 2025. Shanghai RAAS Blood Products Co Ltd Class A's total assets of CN¥37.46 Billion consist of 26.3% current assets and 73.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.6% |
| Accounts Receivable | CN¥2.36 Billion | 6.3% |
| Inventory | CN¥5.37 Billion | 14.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥732.55 Million | 1.9% |
| Goodwill | CN¥8.20 Billion | 21.7% |
Asset Composition Trend (2005–2025)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Shanghai RAAS Blood Products Co Ltd Clas current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai RAAS Blood Products Co Ltd Class A's current assets represent 26.3% of total assets in 2025, a decrease from 73.8% in 2005.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2025, down from 6.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 21.7% of total assets.
Shanghai RAAS Blood Products Co Ltd Class A Competitors by Total Assets
Key competitors of Shanghai RAAS Blood Products Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Shanghai RAAS Blood Products Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.49 | 3.16 | 4.98 |
| Quick Ratio | 2.12 | 1.66 | 2.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥8.24 Billion | CN¥6.76 Billion | CN¥5.49 Billion |
Shanghai RAAS Blood Products Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Shanghai RAAS Blood Products Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.99 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 12.4% |
| Total Assets | CN¥37.80 Billion |
| Market Capitalization | $4.56 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai RAAS Blood Products Co Ltd Class A's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shanghai RAAS Blood Products Co Ltd Class A's assets grew by 12.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
The table below shows the annual total assets of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥37.80 Billion ≈ $5.53 Billion |
+12.41% |
| 2024-12-31 | CN¥33.63 Billion ≈ $4.92 Billion |
+5.33% |
| 2023-12-31 | CN¥31.93 Billion ≈ $4.67 Billion |
+4.83% |
| 2022-12-31 | CN¥30.46 Billion ≈ $4.46 Billion |
+11.83% |
| 2021-12-31 | CN¥27.24 Billion ≈ $3.99 Billion |
+6.84% |
| 2020-12-31 | CN¥25.49 Billion ≈ $3.73 Billion |
+115.08% |
| 2019-12-31 | CN¥11.85 Billion ≈ $1.73 Billion |
+4.01% |
| 2018-12-31 | CN¥11.40 Billion ≈ $1.67 Billion |
-21.16% |
| 2017-12-31 | CN¥14.46 Billion ≈ $2.12 Billion |
+9.30% |
| 2016-12-31 | CN¥13.23 Billion ≈ $1.94 Billion |
+14.45% |
| 2015-12-31 | CN¥11.56 Billion ≈ $1.69 Billion |
+23.21% |
| 2014-12-31 | CN¥9.38 Billion ≈ $1.37 Billion |
+495.47% |
| 2013-12-31 | CN¥1.58 Billion ≈ $230.49 Million |
+30.36% |
| 2012-12-31 | CN¥1.21 Billion ≈ $176.81 Million |
+19.69% |
| 2011-12-31 | CN¥1.01 Billion ≈ $147.73 Million |
+8.51% |
| 2010-12-31 | CN¥930.33 Million ≈ $136.14 Million |
+12.74% |
| 2009-12-31 | CN¥825.22 Million ≈ $120.76 Million |
-0.72% |
| 2008-12-31 | CN¥831.19 Million ≈ $121.63 Million |
+171.15% |
| 2007-12-31 | CN¥306.54 Million ≈ $44.86 Million |
-5.73% |
| 2006-12-31 | CN¥325.16 Million ≈ $47.58 Million |
-2.54% |
| 2005-12-31 | CN¥333.63 Million ≈ $48.82 Million |
-- |
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinoge… Read more